We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.55%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.22B
AUM Growth
+$106M
Cap. Flow
+$6.46M
Cap. Flow %
0.53%
Top 10 Hldgs %
47.36%
Holding
68
New
14
Increased
14
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$40.8M
2
ABBV icon
AbbVie
ABBV
+$33.3M
3
HCA icon
HCA Healthcare
HCA
+$31.2M
4
CI icon
Cigna
CI
+$27.4M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$25.7M

Top Sells

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$50.3M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$41.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$21.6M
4
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$21.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 86.79%
2 Miscellaneous 7.72%
3 Financials 2.76%
4 Communication Services 1.41%
5 Technology 1.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
51
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.87M 0.15%
+12,328
New +$2.04M
IHF icon
52
iShares US Healthcare Providers ETF
IHF
$1.31B
$1.23M 0.1%
42,995
– –
CLDX icon
53
Celldex Therapeutics
CLDX
$3.12B
$826K 0.07%
2,184
-34,283
-94% -$13.6M
PPH icon
54
VanEck Pharmaceutical ETF
PPH
$1.05B
$460K 0.04%
6,500
– –
ABUS icon
55
Arbutus Biopharma
ABUS
$1.02B
– –
-700,000
Closed -$12.2M
ARAY icon
56
Accuray
ARAY
$31.9M
– –
-1,515,475
Closed -$14.1M
GMED icon
57
Globus Medical
GMED
$10.5B
– –
-611,731
Closed -$15.4M
OPCH icon
58
Option Care Health
OPCH
$3.63B
– –
-344,550
Closed -$6.11M
QQQ icon
59
Invesco QQQ Trust
QQQ
$490B
– –
-4,300
Closed -$454K
NUVA
60
DELISTED
NuVasive, Inc.
NUVA
– –
-185,137
Closed -$8.51M
OTIC
61
DELISTED
Otonomy, Inc.
OTIC
– –
-78,972
Closed -$2.79M
ENDP
62
DELISTED
Endo International plc
ENDP
– –
-560,443
Closed -$50.3M
TVTY
63
DELISTED
Tivity Health, Inc. Common Stock
TVTY
– –
-1,074,033
Closed -$21.2M
ALXN
64
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-1,390
Closed -$241K
AKAO
65
DELISTED
Achaogen Inc
AKAO
– –
-398,340
Closed -$3.89M
ASPX
66
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
– –
-417,533
Closed -$41.9M
WOOF
67
DELISTED
VCA Inc.
WOOF
– –
-307,804
Closed -$16.9M
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2015 Portfolio in Review

As of Q2 2015, Redmile Group held 68 positions worth $1.22B, up 9.6% from $1.11B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Redmile Group's Q2 2015 filing shows 14 new, 14 increased, 24 reduced and 13 closed positions. Its largest new stake was Allergan plc: 136,818 shares worth $41.5M. The largest sale was Endo International plc, an estimated $50.3M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 82% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q2 2015 buy was Allergan plc: 136,818 shares worth $41.5M.
  • Redmile Group added most to Bausch Health in Q2 2015, an estimated $25.7M increase.
  • Redmile Group's biggest Q2 2015 reduction was Seagen Inc. Common Stock, cutting an estimated $21.6M.
  • Redmile Group fully exited Endo International plc in Q2 2015, selling an estimated $50.3M.
  • Redmile Group's ten largest holdings make up 47% of its $1.22B portfolio in Q2 2015.
  • Redmile Group opened 14 new positions and closed 13 in Q2 2015.
  • Redmile Group's portfolio value rose 9.6% quarter-over-quarter to $1.22B.

Based on Redmile Group's 13F filing for Q2 2015, filed 14 Aug 2015.